학술논문
Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer
Document Type
Article
Author
Ricciuti, Biagio; Naqash, Abdul Rafeh; Naidoo, Jarushka; Sehgal, Kartik; Miller, Adam; Kehl, Kenneth; Venkatraman, Deepti; Sands, Jacob; Lamberti, Giuseppe; Recondo, Gonzalo; Zhang, Jiajia; Macherla, Shravanti; Baig, Sameer; Walker, Paul; Rangachari, Deepa; Gainor, Justin F.; Costa, Daniel B.; Rizvi, Naiyer; Sholl, Lynette M.; Nishino, Mizuki; Henick, Brian; Farago, Anna F.; Awad, Mark M.
Source
JTO Clinical and Research Reports; 20240101, Issue: Preprints
Subject
Language
ISSN
26663643
Abstract
The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and non-small cell lung cancer. Whether this association exists in patients with small cell lung cancer (SCLC) is currently unknown.